Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o1/o7/96 \ \ Origin: Appendix 5 \ \ Amended o1/o7/98, o1/o9/99, o1/o7/o0, 30/o9/o1, 11/o3/o2, o1/o1/o3, 24/10/o5, o1/o8/12, o4/o3/13$

Name o	of entity	
Orion	Health Group Limited (OHE)	
ABN ARBN	I 602 424 386	
We (t	he entity) give ASX the followin	g information.
	1 - All issues ust complete the relevant sections (attack	h sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Ordinary Shares in OHE
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	OHE will issue 35,541,112 Shares (New Shares) pursuant to a Rights Offer.
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares ranking pari passu with other ordinary shares

⁺ See chapter 19 for defined terms.

Do the *securities rank equally From the issue date, the New Shares will in all respects from the +issue rank equally in all respect with the existing date with an existing +class of fully paid ordinary shares in OHE. quoted +securities? If the additional *securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Issue price or consideration A\$0.85 5 NZ\$0.90 Based on NZD/AUD exchange rate as at 29 May 2017 6 Purpose of the issue The net proceeds of the Rights Offer will be (If issued as consideration for used for working capital purposes. the acquisition of assets, clearly identify those assets) 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder N/A resolution under rule 7.1A was passed Number of *securities issued 6с N/A without security holder approval

under rule 7.1

Appendix 3B Page 2

⁺ See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
бе	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	, , , , , , , , , , , , , , , , , , ,
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	⁺ Issue dates	Tuesday, 4 July 2017	
1	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	raesuay, 4 july 2017	
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	195,482,368	Ordinary Shares
			-

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class	
2,911,998	Restricted Units	Stock

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) As for all ordinary shares.

Part 2 - Pro rata issue

11 Is security holder approval required?

No

Is the issue renounceable or nonrenounceable?

Renounceable

Ratio in which the *securities will be offered

2 for 9

⁺Class of ⁺securities to which the offer relates

Ordinary shares

15 ⁺Record date to determine entitlements

7.00 pm (New Zealand time) on Thursday 8 June 2017

16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

No

Policy for deciding entitlements in relation to fractions

Entitlements to fractions of New Shares were rounded down to the nearest Share.

Names of countries in which the entity has security holders who will not be sent new offer documents

All countries other than Australia and New Zealand.

Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

19 Closing date for receipt acceptances or renunciations

7.00 pm (New Zealand time), Thursday, 29 June 2017

Appendix 3B Page 4

⁺ See chapter 19 for defined terms.

20	Names of any underwriters	First NZ Capital Securities Limited
21	Amount of any underwriting fee or commission	An underwriting fee of 2.0% of the total gross proceeds to be raised under the Offer (excluding proceeds received from the participation of OHE's significant shareholders who have previously committed to take up their Rights) and a lead management fee of up to 1.25%, of the total gross proceeds to be raised under the Offer.
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	A stamping fee of 0.5% of Application Monies on New Shares allotted will be paid to NZX Firms who submit a valid claim for a broker stamping fee on successful Applications. (subject to a maximum of \$250). In the event that the total broker stamping fees payable exceed \$20,000, the payment will be scaled back on a pro rata basis.
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Tuesday, 13 June 2017
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	Rights trading on the NZX Main Board will began on Wednesday 7 June 2017. Rights were not quoted on ASX and did not trade on ASX.

⁺ See chapter 19 for defined terms.

29 Date rights trading will end (if applicable)

Rights trading on the NZX Main Board ceased on Friday, 23 June 2017. Rights were not quoted on ASX and did not trade on ASX.

How do security holders sell their entitlements *in full* through a broker?

By instructing an NZX Primary Market Participant to sell their Rights on the NZX Main Board on their behalf.

How do security holders sell part of their entitlements through a broker and accept for the balance?

- Instructing an NZX Primary Market Participant to sell the number of Rights the securityholder wished to renounce; and
- indicate the number of New Shares they wished to take up on the Acceptance Form and sending the completed Acceptance Form, together with payment for the number of New Shares applied for, directly to the NZX Primary Market Participant through whom the securityholder sold their Rights.

⁺ See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	To undertake an off-market transfer, the holder must have completed the relevant section of the Acceptance Form in accordance with the instructions on that form and sent it to the buyer of the Rights for completion by them. They must have returned the Acceptance Form to the Registrar together with the Application Monies by no later than 7.00pm on the Closing Date.
33	⁺ Issue	e date	Tuesday, 4 July 2017
		uotation of securitie	
34	Type (tick o	of ⁺ securities one)	
(a)	+Securities described in Part 1		
(b)	All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entitie	es tha	t have ticked box 34(a)	
Addit	ional	securities forming a new	class of securities
Tick to docume		e you are providing the informat	ion or
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders		
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over		
37		A copy of any trust deed for	the additional ⁺ securities

⁺ See chapter 19 for defined terms.

Entitio	Entities that have ticked box 34(b)				
38	Number of *securities for which *quotation is sought				
39	⁺ Class of ⁺ securities for which quotation is sought	,			
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		X.		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify that other *security)				
		Number	⁺ Class		
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)				

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4	We give ASX the information and documents required by this form. If an
	information or document is not available now, we will give it to ASX befor
	⁺ quotation of the †securities begins. We acknowledge that ASX is relying o
	the information and documents. We warrant that they are (will be) true an
	complete.
	/

== == == == ==

Sign here:	(Director /Company secretary)	. Date:	30/06/1
Print name:	Ian McCrae		

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	N/A	
 Add the following: Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which 	N/A	
 this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid *ordinary securities cancelled during that 12 month period	N/A	
"A"	N/A	

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	N/A	
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.1	
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	N/A	
Under an exception in rule 7.2		
Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	N/A	
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15	N/A	
Note: number must be same as shown in Step 2		
Subtract "C"	N/A	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" × 0.15] – "C"	N/A	
	[Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
"A"	N/A		
Note: number must be same as shown in Step 1 of Part 1			
Step 2: Calculate 10% of "A"			
"D"	0.10		
	Note: this value cannot be changed		
Multiply "A" by 0.10	N/A		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used			
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	N/A		
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 			
"E"	N/A		

Appendix 3B Page 12

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	N/A	
Note: number must be same as shown in Step 2		
Subtract "E"	N/A	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" × 0.10] – "E"	N/A	
	Note: this is the remaining placement capacity under rule 7.1A	

⁺ See chapter 19 for defined terms.